APA (7th ed.) Citation

Vansteenkiste, J., Demedts, I., Pons-Tostivint, E., Biesma, B., Borm, F., Colinet, B., . . . Sibille, A. (2022). 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC). Annals of Oncology, 33, S1086. https://doi.org/10.1016/j.annonc.2022.07.1299

Chicago Style (17th ed.) Citation

Vansteenkiste, J.F, et al. "1176P Open-label, Dose Escalation, Phase I/II Study to Assess Safety, Tolerability, Immunogenicity and Preliminary Clinical Activity of the Therapeutic Cancer Vaccine PDC*lung01 with or Without Anti-programmed Death-1 (PD-1) Treatment in Patients with Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology 33 (2022): S1086. https://doi.org/10.1016/j.annonc.2022.07.1299.

MLA (9th ed.) Citation

Vansteenkiste, J.F, et al. "1176P Open-label, Dose Escalation, Phase I/II Study to Assess Safety, Tolerability, Immunogenicity and Preliminary Clinical Activity of the Therapeutic Cancer Vaccine PDC*lung01 with or Without Anti-programmed Death-1 (PD-1) Treatment in Patients with Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology, vol. 33, 2022, p. S1086, https://doi.org/10.1016/j.annonc.2022.07.1299.